文献速递冠心病外科

新型生物修复聚合物冠状动脉旁路移植管道的一年通畅率

One-year patency of a novel biorestorative polymeric coronary artery bypass conduit.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2024-01-01

本文报告一例70岁三支血管病变男性患者,在常规CABG术中植入新型生物修复聚合物管道XABG,术后6个月TIMI 3级血流通畅,12个月心脏CT确认通畅,旨在展示该管道的安全性和可行性。

要点

  • XABG管道在常规CABG术中植入安全可行。
  • 术后6个月TIMI 3级血流,12个月CT确认通畅。
  • 需更大样本验证其长期通畅率及临床获益。

核心结论

  • XABG管道在常规CABG术中植入安全可行,12个月保持通畅。

研究设计与样本

  • 病例报告:70岁三支血管病变男性患者,常规CABG术中植入XABG管道。

主要发现

  • 术后6个月管道通畅,TIMI 3级血流。
  • 术后12个月心脏CT确认管道通畅。

临床怎么用

  • XABG作为即用型小直径血管管道,可能为CABG提供替代选择,但需进一步研究验证。

局限性

  • 单例病例报告,无法评估长期通畅率及广泛适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery bypass graft (CABG) surgery remains the gold standard in the treatment of complex coronary artery disease. Saphenous vein grafts (SVG) are commonly used for the non-left anterior descending artery. However, SVG failure rates in CABG surgery have been reported to be as high as 30% at 1 year and ∼50% at 10 years. Despite suboptimal performance, ∼80% of all CABG surgery includes SVG graft use. Therefore, an off-the-shelf, small-diameter vascular conduit with good patency rates remains a large unmet clinical need. XABG (Xeltis BV, Eindhoven, The Netherlands), a novel supramolecular electrospun biorestorative polymeric conduit with an embedded nitinol microskeleton, is under clinical development to fulfill this unmet need. This case report aims to demonstrate the safety and feasibility of this conduit in a routine CABG operation with implantation in a 70-year-old male patient with three-vessel disease. The XABG conduit remained patent with TIMI 3 flow at 6 months, and patency was confirmed by cardiac computed tomography at 12 months.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. George I, Neves P, Cox M, et al. One-year patency of a novel biorestorative polymeric coronary artery bypass conduit. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 39798138. doi:10.1093/icvts/ivaf006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。